DFTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Definium Therapeutics Inc (DFTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising analyst ratings and potential catalysts, the lack of positive financial performance, absence of recent trading signals, and current price decline suggest waiting for more favorable conditions before investing.
The stock closed at $17.29, down 1.87% during the regular market session and 1.02% in pre-market trading. Post-market showed a slight recovery of 0.57%. There is no clear upward trend, and the price movement indicates bearish sentiment in the short term.
Analysts have given strong ratings with price targets ranging from $25 to $37, citing high confidence in the efficacy of DT120 in Phase III trials and its potential in Major Depression Disorder.
The company has fully enrolled patients in its Emerge trial, with topline data expected by late Q2 2026, which could act as a catalyst.
The firm has a solid cash position of $411.6 million, which supports ongoing R&D activities.
The company reported significant R&D expenses of $117.7 million for 2025, contributing to a negative EPS of -$0.
Revenue remains at $0, and net income is deeply negative at -$67.27 million, despite YoY improvement.
The stock's recent price decline and lack of upward momentum indicate weak short-term sentiment.
In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of $67.27 million (improved by 391.56% YoY), and an EPS of -$0.78 (improved by 333.33% YoY). Gross margin remains at 0%. The company is heavily reliant on R&D investments and has yet to generate revenue.
Analysts have initiated coverage with strong ratings and high price targets, ranging from $25 to $37. Wolfe Research, Jefferies, Baird, and RBC Capital all see significant potential in the company's lead drug DT120, particularly in the psychedelics and central nervous system therapeutic areas.
